AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24081128 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term indwelling urinary catheter intervention
Number of subjects: 0
Study 21439804 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppb ozone exposure for 3 hours with intermittent exercise
Number of subjects: 14
Study 21439804 — intervention group
Group type: COMPARATOR
Intervention: Filtered room air exposure for 3 hours with intermittent exercise
Number of subjects: 14
Study 21439804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyranose 320(®) eNose analysis
Number of subjects: 14
Study 19005935 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrity asthma messages (experimental group)
Number of subjects: 28
Study 19005935 — intervention group
Group type: COMPARATOR
Intervention: General health messages (control group)
Number of subjects: 28
Study 16601995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 112
Study 16601995 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 112
Study 16601995 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 112
Study 16601995 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride
Number of subjects: 112
Study 15055472 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients (n=33)
Number of subjects: 93
Study 15055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirsute women (PCOS and IH combined, n=73)
Number of subjects: 93
Study 15055472 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with hyperandrogenemia
Number of subjects: 93
Study 15055472 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n=20)
Number of subjects: 93
Study 10942184 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline at 1000 hours
Number of subjects: 12
Study 10942184 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline at 2200 hours
Number of subjects: 12
Study 10942184 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline (both treatments)
Number of subjects: 12
Study 8798112 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-leg training group
Number of subjects: 21
Study 8798112 — intervention group
Group type: EXPERIMENTAL
Intervention: One-leg training group
Number of subjects: 21
Study 8798112 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 1616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg)
Number of subjects: 50
Study 1616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg)
Number of subjects: 50
Study 1616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (50 mg)
Number of subjects: 50
Study 1616168 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (100 mg)
Number of subjects: 50
Study 1616168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 50
Study 6611603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 200 mg/day
Number of subjects: 6
Study 6611603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg/day
Number of subjects: 6
Study 6611603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 400 mg/day
Number of subjects: 6
Study 6611603 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil (all dosages)
Number of subjects: 6
Study 30079573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A (targeted at improving information provision)
Number of subjects: 37
Study 30079573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention B (targeted at improving collaborative goal setting)
Number of subjects: 37
Study 30079573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention A
Number of subjects: 37
Study 26865514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichlorphenamide (DCP)
Number of subjects: 65
Study 26865514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 24225126 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate with flumazenil (group F, n=20)
Number of subjects: 40
Study 24225126 — intervention group
Group type: COMPARATOR
Intervention: Etomidate without flumazenil (group E, n=20)
Number of subjects: 40
Study 22789494 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 38
Study 22789494 — intervention group
Group type: EXPERIMENTAL
Intervention: Static applanation resonance tonometry (ART)
Number of subjects: 38
Study 22789494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry (DCT)
Number of subjects: 38
Study 22789494 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic applanation resonance tonometry (ART)
Number of subjects: 38
Study 20345546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 microg once daily into each nostril for 3 months
Number of subjects: 217
Study 20345546 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray once daily into each nostril for 3 months
Number of subjects: 217
Study 18280329 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive model targeting all children aged 6-23 months
Number of subjects: 1500
Study 18280329 — intervention group
Group type: COMPARATOR
Intervention: Recuperative model targeting underweight children aged 6-60 months
Number of subjects: 1500
Study 15877290 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose growth hormone (GH) administration for 4 hours
Number of subjects: 12
Study 15877290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH administration)
Number of subjects: 12
Study 12544508 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (angiotensin II type 1 receptor blocker)
Number of subjects: 97
Study 12544508 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta 1-adrenergic receptor blocker)
Number of subjects: 97
Study 11827617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral treatment including education about memory loss, relaxation training, memory skills training, and cognitive restructuring for memory-related beliefs.
Number of subjects: 0
Study 11827617 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 0
Study 10481831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0 to 0.8 microgram/kg)
Number of subjects: 0
Study 8526782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine oros 30 mg/day
Number of subjects: 203
Study 8526782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine oros 60 mg/day (for non-responders)
Number of subjects: 203
Study 8526782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine oros
Number of subjects: 203
Study 2191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (0.2 mg daily)
Number of subjects: 68
Study 2191779 — intervention group
Group type: COMPARATOR
Intervention: Oral captopril (122.9 mg daily)
Number of subjects: 68
Study 2191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 68
Study 2191779 — intervention group
Group type: COMPARATOR
Intervention: Oral captopril
Number of subjects: 68
Study 2191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine and Oral captopril
Number of subjects: 68
Study 6769158 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 36
Study 6769158 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 36
Study 31617025 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PPF/SCF ratio (≥ 1)
Number of subjects: 85
Study 31617025 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PPF/SCF ratio (< 1)
Number of subjects: 85
Study 31170680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hépar (1 L daily for 14 days)
Number of subjects: 226
Study 31170680 — intervention group
Group type: COMPARATOR
Intervention: Low-mineral water (1 L daily for 14 days)
Number of subjects: 226
Study 31170680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hépar
Number of subjects: 226
Study 31170680 — intervention group
Group type: COMPARATOR
Intervention: Low-mineral water
Number of subjects: 226
Study 28340302 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy expenditures from different types of breaks (standing, light‐ or moderate‐intensity walking)
Number of subjects: 0
Study 25982590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 30 min
Number of subjects: 98
Study 25982590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) infused over 15 min
Number of subjects: 98
Study 25982590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carbamazepine (administered at 70% of the oral dosage, mean 675.1 mg) with rapid infusions (2-5 min)
Number of subjects: 98
Study 25982590 — intervention group
Group type: COMPARATOR
Intervention: Oral carbamazepine (mean 962.5 mg)
Number of subjects: 98
Study 23551697 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume measurement
Number of subjects: 1758
Study 21228335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 315
Study 19825050 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoFlex tracheal tube
Number of subjects: 50
Study 18162722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 164
Study 18162722 — intervention group
Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 164
Study 15166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 25 ng.kg(‐1).min(‐1)
Number of subjects: 32
Study 15166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 50 ng.kg(‐1).min(‐1)
Number of subjects: 32
Study 15166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 100 ng.kg(‐1).min(‐1)
Number of subjects: 32
Study 15166555 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 32
Study 15166555 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in combination with remifentanil
Number of subjects: 32
Study 11819165 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en Y reconstruction with pouch
Number of subjects: 164
Study 11819165 — intervention group
Group type: COMPARATOR
Intervention: Roux-en Y reconstruction without pouch
Number of subjects: 164
Study 11819165 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoperistaltic jejunum interposition with pouch
Number of subjects: 164
Study 11819165 — intervention group
Group type: COMPARATOR
Intervention: Isoperistaltic jejunum interposition without pouch
Number of subjects: 164
Study 11819165 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en Y reconstruction with jejunum interposition with pouch
Number of subjects: 164
Study 9622434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 118
Study 9622434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 9622434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate with disulfiram
Number of subjects: 118
Study 8160990 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of fentanyl
Number of subjects: 62
Study 8160990 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free normal saline (placebo group)
Number of subjects: 62
Study 3277912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg)
Number of subjects: 27
Study 3277912 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (50 mg)
Number of subjects: 27
Study 3277912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (160 mg)
Number of subjects: 27
Study 3277912 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorthalidone and triamterene
Number of subjects: 27
Study 3277912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 3277912 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 27
Study 30347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 0
Study 30347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 0
Study 30347966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 0
Study 30347966 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 27188814 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg DHA/day (3 capsules daily)
Number of subjects: 2399
Study 27188814 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil placebo
Number of subjects: 2399
Study 25539637 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation-based cognitive stimulation delivered through personal computers, a webcam and the internet
Number of subjects: 1102
Study 25539637 — intervention group
Group type: COMPARATOR
Intervention: Committed with interest group
Number of subjects: 1102
Study 22409211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine 7.5 mg twice daily for 5 days
Number of subjects: 40
Study 22409211 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days
Number of subjects: 40
Study 20798615 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice in facility design
Number of subjects: 0
Study 20798615 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical appraisal of facility design research articles
Number of subjects: 0
Study 18684258 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tilt biphasic waveform
Number of subjects: 0
Study 18684258 — intervention group
Group type: COMPARATOR
Intervention: Conventional waveform
Number of subjects: 0
Study 15916852 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect *G condition (e.g., He happened using it)
Number of subjects: 10
Study 15916852 — intervention group
Group type: COMPARATOR
Intervention: Grammatical versions
Number of subjects: 10
Study 15916852 — intervention group
Group type: COMPARATOR
Intervention: Incorrect *I condition (e.g., He postponed to use it)
Number of subjects: 10
Study 15531473 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment at 1 or 2 mg GH/m² body surface.d (approximately 0.035 or 0.07 mg/kg.d)
Number of subjects: 74
Study 15531473 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 74
Study 10882848 — intervention group
Group type: EXPERIMENTAL
Intervention: PKA regulatory subunits type I (RI) and type II (RII) in patients with schizophrenia
Number of subjects: 12
Study 10882848 — intervention group
Group type: COMPARATOR
Intervention: PKA regulatory subunits type I (RI) and type II (RII) in controls
Number of subjects: 12
Study 10882848 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalytic (C) subunit of PKA in patients with schizophrenia
Number of subjects: 12
Study 10882848 — intervention group
Group type: COMPARATOR
Intervention: Catalytic (C) subunit of PKA in controls
Number of subjects: 12
Study 8881628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 99
Study 8881628 — intervention group
Group type: COMPARATOR
Intervention: 1% propofol and 0.5% methohexitone mixture
Number of subjects: 99
Study 1529635 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression stockings
Number of subjects: 49
Study 1529635 — intervention group
Group type: COMPARATOR
Intervention: Control (no stockings)
Number of subjects: 49
Study 3924084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alfentanil anaesthesia (150 micrograms kg‐1 initially, followed by continuous infusion at a rate of 3 micrograms kg‐1 min‐1)
Number of subjects: 24
Study 3924084 — intervention group
Group type: COMPARATOR
Intervention: Neurolept anaesthesia (droperidol 0.25 mg kg‐1 plus fentanyl 5 micrograms kg‐1 initially, followed by intermittent incremental doses of fentanyl 50 micrograms)
Number of subjects: 24
Study 3924084 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alfentanil anaesthesia
Number of subjects: 24
Study 2455132 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (120 mg b.i.d.)
Number of subjects: 12
Study 2455132 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg b.i.d.)
Number of subjects: 12
Study 31439812 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 100 mg
Number of subjects: 36
Study 31439812 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Number of subjects: 36
Study 31439812 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg
Number of subjects: 36
Study 31439812 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (all doses)
Number of subjects: 36
Study 31619124 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-based educational intervention
Number of subjects: 213
Study 31619124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 213
Study 28059942 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMG-BF)
Number of subjects: 20
Study 28059942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 25164268 — intervention group
Group type: EXPERIMENTAL
Intervention: P50 (50% maximal tolerable torque)
Number of subjects: 17
Study 25164268 — intervention group
Group type: EXPERIMENTAL
Intervention: P75 (75% maximal tolerable torque)
Number of subjects: 17
Study 25164268 — intervention group
Group type: EXPERIMENTAL
Intervention: P100 (maximum intensity without pain)
Number of subjects: 17
Study 25164268 — intervention group
Group type: COMPARATOR
Intervention: Comparison of protocols for the same time under stretch
Number of subjects: 17
Study 25164268 — intervention group
Group type: EXPERIMENTAL
Intervention: P50, P75, P100
Number of subjects: 17
Study 23497162 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aquatic resistance exercise program (1-hour duration, 3 times a week for four months)
Number of subjects: 80
Study 23497162 — intervention group
Group type: COMPARATOR
Intervention: Normal care during the intervention period
Number of subjects: 80
Study 21317163 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial interventions (subject involvement, weekly phone reminders, routine counselling)
Number of subjects: 76
Study 21317163 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling only
Number of subjects: 76
Study 18295975 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRST
Number of subjects: 371
Study 18295975 — intervention group
Group type: EXPERIMENTAL
Intervention: MEAL
Number of subjects: 371
Study 18295975 — intervention group
Group type: EXPERIMENTAL
Intervention: LAST
Number of subjects: 371
Study 18295975 — intervention group
Group type: EXPERIMENTAL
Intervention: ROUTINE
Number of subjects: 371
Study 18295975 — intervention group
Group type: EXPERIMENTAL
Intervention: ENHANCE
Number of subjects: 371
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide (250 mg or 500 mg, six times a week)
Number of subjects: 50
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothionamide (250 mg or 500 mg, six times a week)
Number of subjects: 50
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethionamide (500 mg)
Number of subjects: 50
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothionamide (500 mg)
Number of subjects: 50
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothionamide (both dose levels)
Number of subjects: 50
Study 16525107 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall killing of M. leprae
Number of subjects: 50
Study 12395939 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week multidisciplinary rehabilitation programme emphasizing physiotherapy
Number of subjects: 43
Study 12395939 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 43
Study 10217586 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD (PS-protein conjugate with diphtheria toxoid)
Number of subjects: 0
Study 10217586 — intervention group
Group type: EXPERIMENTAL
Intervention: PncT (PS-protein conjugate with tetanus protein)
Number of subjects: 0
Study 10217586 — intervention group
Group type: EXPERIMENTAL
Intervention: PncCRM (PS-protein conjugate with CRM197 protein)
Number of subjects: 0
Study 10217586 — intervention group
Group type: COMPARATOR
Intervention: 23-valent PS vaccine (control group)
Number of subjects: 0
Study 7788929 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 or 400 micrograms of budesonide powder b.i.d.
Number of subjects: 126
Study 7788929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 2149389 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg once daily)
Number of subjects: 38
Study 2149389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic 1
Number of subjects: 102
Study 370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic 2
Number of subjects: 102
Study 370178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic 3
Number of subjects: 102
Study 370178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 29576624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 658
Study 29576624 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg daily)
Number of subjects: 658
Study 26220149 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose of rapid‐acting insulin (2 ± 1 units, range 0‐4 units) administered immediately after resistance exercise
Number of subjects: 8
Study 26220149 — intervention group
Group type: COMPARATOR
Intervention: No insulin administered after resistance exercise
Number of subjects: 8
Study 24748530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot (35 °C/40 % rH)
Number of subjects: 11
Study 24748530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 0.15)
Number of subjects: 11
Study 24748530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot + Hypoxia (35 °C/40 % rH + FiO2 0.15)
Number of subjects: 11
Study 24748530 — intervention group
Group type: COMPARATOR
Intervention: Control (temperate/sea level)
Number of subjects: 11
Study 24748530 — intervention group
Group type: EXPERIMENTAL
Intervention: All trials compounded (pre- to post-exercise)
Number of subjects: 11